Parameswaran Hari, MD, MRCP, the Armand J. Quick/William F. Stapp Professor of Hematology, and the chief of the Division of Hematology/Oncology, Department of Medicine, at the Medical College of Wisconsin...Continue Reading

A series of molecular abnormalities in smoldering multiple myeloma that are independent predictors of progression to multiple myeloma were accurately identified in a genomic test of bone marrow tissue, according to a study led by researchers at the Dana-Farber Cancer Institute and published in the Journal of Clinical Oncology.1,2 Patients identified with these alterations can be closely...Continue Reading

Myeloma Australia’s Medical and Scientific Advisory Group (MSAG) presents the article of the week. Lenalidomide, bortezomib, and dexamethasone (RVd) followed by autologous stem cell transplantation (ASCT) is standard frontline therapy for transplant-eligible patients with newly diagnosed multiple myeloma (NDMM). This study evaluated addition of daratumumab (D) to RVd in ASCTeligible NDMM patients. Patients (N=207) were randomized...Continue Reading

Highlights include: Associations with OS in NZ MM patients VTE risk with lenalidomide regimens for MM despite thromboprophylaxis Retrospective study of with t(14;16) MM Download here: Multiple Myeloma Research Review Issue 34Continue Reading

Real world experience with early bortezomib therapy in multiple myeloma in Australia suggests that it is used in patients who are older and more vulnerable than those in clinical trials. A retrospective review has reported data from 74 patients at three Queensland hospitals who had newly diagnosed multiple myeloma ineligible for autologous stem cell transplantation who were...Continue Reading

Myeloma Australia’s Medical and Scientific Advisory Group (MSAG) presents the article of the week. Multiple myeloma (MM) is the third most common hematologic malignancy worldwide, characterized by excessive proliferation of monoclonal plasma cells. The development of novel anti-MM agents has expanded treatment options for MM patients and improved out-comes. Despite recent treatment advances, MM remains incurable, with...Continue Reading

The FDA has approved a new subcutaneous formulation of daratumumab and hyaluronidase-fihj for adult patients with newly-diagnosed or relapsed/refractory multiple myeloma (MM). Daratumumab was previously approved as an intravenous treatment for patients with MM. The combination of daratumumab and hyaluronidase-fihj is co-formulated with recombinant human hyaluronidase PH20 to allow subcutaneous injection. The treatment is approved...Continue Reading

Hello Everybody I hope that you are all coping with the lock-down as best that you can. It’s been a difficult time for many people and especially those that have had to have treatment delays such as auto transplants. We were very pleased to be involved with the press releases for the Lenalidomide Post ASCT...Continue Reading

The Patient Voice Aotearoa team, with support from 35 patient advocacy groups, today published a full page ad in the Herald calling on the Prime Minister and her government to urgently fund medicines to save the lives of our most vulnerable, defenceless citizens during Covid-19. Myeloma New Zealand are proud to support the open letter, and...Continue Reading

Myeloma Australia’s Medical and Scientific Advisory Group (MSAG) presents the article of the week. The article from Australia’s National Centre for Infections in Cancer (NCIC, Peter MacCallum Cancer Centre) includes MSAG members Prof Jeff Szer and A/Prof Peter Mollee as co-authors.  Along with this guide for health care professionals please find attached the guide for patients, produced by...Continue Reading